June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.
Author Affiliations & Notes
  • Serena Salvatore
    Medical Retina Department, Bristol Eye Hospital, University Hospitals Bristol, Bristol, United Kingdom
  • Clare Bailey
    Medical Retina Department, Bristol Eye Hospital, University Hospitals Bristol, Bristol, United Kingdom
  • Usha Chakravarthy
    Queen’s University Belfast, Belfast, Ireland
  • Andrew J Lotery
    University of Southampton, Southampton, United Kingdom
  • Geeta Menon
    Frimley Park Hospital, Portsmouth, United Kingdom
  • James Talks
    Royal Victoria Hospital Newcastle upon Tyne, Newcastle Upon Tyne, United Kingdom
  • Footnotes
    Commercial Relationships   Serena Salvatore, Allergan (F); Clare Bailey, Alcon (F), Alimera Sciences (F), Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R); Usha Chakravarthy, Alimera Sciences (R), Allergan (R), Bayer (R), Bayer (F), Novartis (F), Novartis (R), Roche (F), Rocher (R); Andrew Lotery, Bayer (C), Bayer (R), Gyroscope Therapeutics (C); Geeta Menon, Bayer (R), Novartis (R); James Talks, Alimera Sciences (F), Bayer (F), Bayer (C), Bayer (R)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4631. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Serena Salvatore, Clare Bailey, Usha Chakravarthy, Andrew J Lotery, Geeta Menon, James Talks; The impact of prior steroid therapy on safety outcomes following treatment with ILUVIEN (fluocinolone acetonide) – An analysis of intra-ocular outcomes (IOP) from UK electronic medical records.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4631.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To date, the impact of prior steroid therapy on the safety outcomes with ILUVIEN has not been reported in real-world clinical practice. This post-hoc analysis assessed the correlation of prior ocular steroid exposure with incidence of IOP elevations (>30mmHg) after intravitreal injection of the ILUVIEN implant.

Methods : The MedisoftTM EMR audit retrospectively collected anonymised patient data from 345 eyes / 305 DMO patients from 14 UK NHS centres and patients data with IOP increase >30 mmHg post-ILUVIEN was statistically analysed to assess the effect of prior steroid exposure as a predictive factor.

Results : Mean follow-up was 428 days. In the whole population, 7.2% of eyes experienced a rise in IOP above 30 mmHg and 13.9% required IOP-lowering drops following ILUVIEN therapy. In the prior steroid group 0% of eyes had a rise in IOP >30 mmHg if there was no history of prior IOP-related events versus 14.5% (P=0.008) if there was a history of prior IOP-related events. Similar findings (P=0.009) were observed in the no prior steroid group with 4.9% vs 14.9% (no history vs an existing history of prior IOP-related events) of eyes experiencing a rise in IOP >30 mmHg (see figures).

Conclusions : This real-world safety data shows the best safety outcomes are achieved in eyes where there is no history of prior IOP-related events. Eyes with prior steroid therapy without secondary IOP rise did not develop an IOP rise to more than 30 mmHg following ILUVIEN.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

IOP-related events in ILUVIEN-treated patients without prior steroid treatment.

IOP-related events in ILUVIEN-treated patients without prior steroid treatment.

 

IOP-related events in ILUVIEN-treated patients with prior steroid treatment.

IOP-related events in ILUVIEN-treated patients with prior steroid treatment.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×